Based on an interim analysis of the Phase II SELECT trial, the anti-CD25 mAb daclizumab recently entered Phase III as a monotherapy for patients with RRMS. Ustekinumab, an inhibitory mAb against ...

Aulos™ Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced the presentation of new data from ...